DYNDyne Therapeutics, Inc.

Nasdaq dyne-tx.com


$ 46.49 $ 1.04 (2.29 %)    

Friday, 23-Aug-2024 15:59:52 EDT
QQQ $ 479.76 $ 5.15 (1.08 %)
DIA $ 411.97 $ 4.35 (1.07 %)
SPY $ 562.00 $ 5.91 (1.06 %)
TLT $ 98.37 $ 0.64 (0.65 %)
GLD $ 231.99 $ 2.65 (1.16 %)
$ 46.53
$ 46.48 x 100
-- x --
-- - --
$ 6.40 - $ 47.45
605,491
na
4.67B
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-02-2024 03-31-2024 10-Q
3 03-05-2024 12-31-2023 10-K
4 10-30-2023 09-30-2023 10-Q
5 08-03-2023 06-30-2023 10-Q
6 05-11-2023 03-31-2023 10-Q
7 03-02-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-04-2022 06-30-2022 10-Q
10 05-02-2022 03-31-2022 10-Q
11 03-10-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-05-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-04-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-maintains-buy-on-dyne-therapeutics-raises-price-target-to-66

Stifel analyst Paul Matteis maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $41 to $66.

 guggenheim-maintains-buy-on-dyne-therapeutics-raises-price-target-to-50

Guggenheim analyst Debjit Chattopadhyay maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from...

 morgan-stanley-maintains-overweight-on-dyne-therapeutics-raises-price-target-to-52

Morgan Stanley analyst Michael Ulz maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target fr...

 tech-stocks-soar-treasury-yields-fall-on-cool-inflation-data-starbucks-rockets-chipotle-plummets-whats-driving-markets-tuesday

A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified e...

 piper-sandler-maintains-overweight-on-dyne-therapeutics-raises-price-target-to-53

Piper Sandler analyst Edward Tenthoff maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target...

 hc-wainwright--co-maintains-buy-on-dyne-therapeutics-raises-price-target-to-55

HC Wainwright & Co. analyst Andrew Fein maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target ...

 dyne-therapeutics-q2-2024-gaap-eps-070-beats-072-estimate

Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0....

 xpeng--quantumscape-are-among-top-11-mid-cap-stocks-that-performed-well-last-week-july-7-july-13-details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeut...

 jp-morgan-maintains-overweight-on-dyne-therapeutics-raises-price-target-to-43

JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target from $...

 soft-inflation-data-boosts-small-caps-real-estate-regional-banks-traders-anticipate-fed-rate-cuts-as-stocks-react

U.S. inflation slowed in May, boosting rate cut prospects. Markets rally ahead of FOMC meeting and assign 70% chance of rate cu...

 reported-earlier-dyne-therapeutics-prices-3255m-public-offering-of-105m-common-stock-at-31share

The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses pay...

 chardan-capital-maintains-buy-on-dyne-therapeutics-raises-price-target-to-42

Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $31 ...

 dyne-therapeutics-announces-300m-public-offering-of-common-stock

Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming...

 why-is-dyne-therapeutics-stock-soaring-on-monday

Dyne Therapeutics reported promising Phase 1/2 trial data for DYNE-101 in myotonic dystrophy type 1 and DYNE-251 in Duchenne mu...

 jefferies-maintains-buy-on-dyne-therapeutics-raises-price-target-to-42

Jefferies maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $36 to $42.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION